

Camilla Hage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4379102/publications.pdf>

Version: 2024-02-01

70
papers

2,221
citations

236925

25
h-index

254184

43
g-index

71
all docs

71
docs citations

71
times ranked

3027
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation science and potential for screening in heart failure. <i>European Heart Journal</i> , 2022, 43, 413-415.	2.2	7
2	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	3.1	5
3	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 681-684.	7.1	16
4	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—Insights from the ESC-HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	7.1	49
5	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	3.1	4
6	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. <i>European Journal of Heart Failure</i> , 2022, 24, 1047-1062.	7.1	37
7	Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. <i>ESC Heart Failure</i> , 2022, 9, 2125-2138.	3.1	3
8	Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the GCHF Research Program. <i>European Journal of Heart Failure</i> , 2022, , .	7.1	4
9	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	4.1	5
10	Effect of dipeptidyl peptidase-4 inhibitors on complement activation. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3385.	4.0	4
11	Reorganization of heart failure management and improved outcome—the 4D HF Project. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 1-8.	1.2	6
12	The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Compliance—Resistance Relationship in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 277-285.	1.7	5
13	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021, 11, 4885.	3.3	31
14	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021, 27, 756-765.	1.7	20
15	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study. <i>ESC Heart Failure</i> , 2021, 8, 4243-4254.	3.1	13
16	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021, 343, 63-72.	1.7	23
17	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. <i>Journal of Cardiac Failure</i> , 2020, 26, 673-684.	1.7	5
18	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117

#	ARTICLE	IF	CITATIONS
19	Metabolomic Profile in HFpEF vs HFrEF Patients. <i>Journal of Cardiac Failure</i> , 2020, 26, 1050-1059.	1.7	46
20	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 1016-1021.	1.7	29
21	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	4.5	38
22	Heart failure with preserved ejection fraction: A clustering approach to a heterogenous syndrome. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 381-390.	1.6	23
23	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. <i>ESC Heart Failure</i> , 2020, 7, 1534-1546.	3.1	28
24	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	2.7	24
25	Increased iron absorption in patients with chronic heart failure and iron deficiency. <i>Journal of Cardiac Failure</i> , 2020, 26, 440-443.	1.7	7
26	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	3.1	23
27	The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study. <i>ESC Heart Failure</i> , 2020, 7, 737-746.	3.1	22
28	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. <i>Heart</i> , 2020, 106, 342-349.	2.9	89
29	Circulating neuregulin1 β in heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 445-455.	3.1	11
30	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. <i>International Journal of Cardiology</i> , 2019, 274, 202-207.	1.7	10
31	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 140, 1359-1361.	1.6	16
32	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 830-839.	3.1	18
33	Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2019, 9, 3179.	3.3	35
34	ST2 in heart failure with preserved and reduced ejection fraction. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 21-27.	1.2	40
35	Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. <i>Clinical Research in Cardiology</i> , 2019, 108, 703-715.	3.3	51
36	Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 302-308.	3.1	12

#	ARTICLE	IF	CITATIONS
37	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. JACC: Heart Failure, 2018, 6, 246-256.	4.1	47
38	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. Journal of Cardiac Failure, 2018, 24, 365-374.	1.7	32
39	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2018, 121, 1558-1566.	1.6	19
40	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. International Journal of Cardiology, 2018, 267, 128-132.	1.7	28
41	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal, 2018, 39, 3439-3450.	2.2	375
42	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	107
43	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2017, 18, 629-635.	1.2	40
44	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. International Journal of Cardiology, 2017, 228, 709-716.	1.7	38
45	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. Heart and Vessels, 2017, 32, 735-749.	1.2	6
46	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. International Journal of Cardiology, 2017, 226, 65-70.	1.7	4
47	Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation. Heart Lung and Circulation, 2017, 26, 143-149.	0.4	9
48	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. Journal of Cardiac Failure, 2017, 23, 293-303.	1.7	25
49	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). International Journal of Cardiology, 2016, 220, 750-758.	1.7	13
50	Rationale and design of the <sc>PREFERS</sc> (Preserved and Reduced Ejection Fraction) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 T Stockholm county of 2.1 million inhabitants. European Journal of Heart Failure, 2016, 18, 1287-1297.	7.1	17
51	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	33
52	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diabetes and Vascular Disease Research, 2016, 13, 307-311.	2.0	6
53	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. European Journal of Heart Failure, 2015, 17, 680-688.	7.1	77
54	Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. Growth Hormone and IGF Research, 2015, 25, 298-303.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	1.7	7
56	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. <i>Heart</i> , 2015, 101, 592-599.	2.9	23
57	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. <i>International Journal of Cardiology</i> , 2015, 189, 6-11.	1.7	17
58	Accuracy of a Simplified Glucose Measurement Device—The HemoCue Glucose 201RT. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 755-758.	4.4	16
59	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. <i>Open Heart</i> , 2015, 2, e000260.	2.3	16
60	Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, .	1.6	0
61	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 290-293.	2.0	13
62	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. <i>Heart</i> , 2014, 100, 1235-1241.	2.9	93
63	Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 992-1001.	7.1	119
64	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 112-121.	1.6	40
65	The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 143-149.	2.0	2
66	Glucose Monitoring by Means of an Intravenous Microdialysis Catheter Technique. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 291-295.	4.4	11
67	The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 145, 259-260.	1.7	13
68	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. <i>Diabetes and Vascular Disease Research</i> , 2009, 6, 71-79.	2.0	20
69	Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 198-204.	7.1	47
70	Long term effects of exercise training on physical activity level and quality of life in elderly coronary patients – A three- to six-year follow-up. <i>Physiotherapy Research International</i> , 2003, 8, 13-22.	1.5	29